5'-Nucleotidase and adenosine deaminase in patients with rheumatoid arthritis

Nela K Zivkovic; Boris Djindjić; Sonja Stojanović; Ivana Krstić; Ivana Ćirić; Tomislav Kostić; Gordana Kocić

doi:10.2298/VSP151125267Z

Nela K Zivkovic Clinical Center Niš, Clinic of Pediatrics, Niš, Serbia
Boris Djindjić University of Niš, Faculty of Medicine, Niš, Serbia
Sonja Stojanović University of Niš, Faculty of Medicine, Niš, Serbia; Institute for Treatment and Rehabilitation “Niška Banja”, Niš, Serbia
Ivana Krstić Institute for Treatment and Rehabilitation “Niška Banja”, Niš, Serbia
Ivana Ćirić University of Niš, Faculty of Medicine, Niš, Serbia
Tomislav Kostić University of Niš, Faculty of Medicine, Niš, Serbia Clinical Center Niš, Clinic of Cardiology, Niš, Serbia
Gordana Kocić University of Niš, Faculty of Medicine, Niš, Serbia

DOI: https://doi.org/10.2298/VSP151125267Z

Keywords: arthritis, rheumatoid, adenosine deaminase, 5'-nucleotidase,

Abstract

Background/Aim. The essence of rheumatoid arthritis (RA) pathogenesis is inflammation, modification of immune system and cell damage. 5'-nucleotidase (5'-NT) and adenosine deaminase (ADA) have a significant role in the process of inflammation-caused tissue damage. The aim of the study is to define 5'-nucleotidase and adenosine deaminase activity in serum of patients with RA treated with methotrexate (MTX) and patients with RA who were not treated with methotrexate, as well as to determine the correlation between the enzymes’ activities and the disease activity. Methods. The study included 160 patients suffering from RA, 60 of them were not treated with methotrexate (average age 56.8 years; 68.3% female) and 100 patients were treated with methotrexate (average age 59.8 years; 88% female), as well as 60 healthy controls (average age 58.8; 66.6% female). Patients suffering from chronic inflammatory diseases, chronic respiratory, cardiac and kidney insufficiency, severe acute diseases and other diseases which might modify inflammatory response were not included in the study. Results. There was no statistically significant difference in 5'-NT values among groups. ADA values were significantly different in all tested groups. Post-hoc analysis (Dunnett’s T3 test) showed that ADA activity in RA groups was significantly higher as compared to that in the control group (p < 0.001), and that ADA activity in the RA group with MTX was significantly smaller as compared to RA group without MTX (p < 0.001). There was not significant correlation between the disease activity and activities of tested enzymes. Conclusion. We concluded that adenosine deaminase activity was increased in patients with rheumatoid arthritis, as well as that the application of methotrexate led to the decrease of this enzyme activity in the serum of patients with rheumatoid arthritis. The activity of 5'-nucleotidase is not increased in patients with rheumatoid arthritis and did not depend on methotrexate treatment. Serum adenosine deaminase and 5'-nucleotidase activities are not good indicators of rheumatoid arthritis activity.

References

Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376(9746): 1094−108.

Montecucco F, Mach F. Common inflammatory mediators or-chestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatol 2009; 48(1): 11−22.

McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365(23): 2205−19.

Haskó G, Cronstein BN. Regulation of inflammation by adeno-sine. Front Immunol 2013; 4: 85.

Haskó G, Linden J, Cronstein B, Pacher P. Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008; 7(9): 759−70.

Ginés S, Mariño M, Mallol J, Canela EI, Morimoto C, Callebaut C, et al. Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminase-CD26 interaction. Biochem J 2002; 361(Pt 2): 203−9.

Tompson LF. 5'-Nucleotidase: an overview of the last three years. In: Harkness RA, Elion GB, Zöllner N, editors. Purine and pyrimidine metabolism in man VII, part B. New York: Pleenum Press; 1992. p. 145−50.

Sunderman FW Jr. The clinical biochemistry of 5'-nucleotidase. Ann Clin Lab Sci 1990; 20(2): 123−39.

American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46(2): 328−46.

Cronstein BN. Going with the flow: Methotrexate, adenosine, and blood flow. Ann Rheum Dis 2006; 65(4): 421−2.

Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007; 65(3): 168−73.

Swierkot J, Szechiński J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006; 58(4): 473−92.

van Ede AE, Laan RF, De Abreu RA, Stegeman AB, van de Putte LB. Purine enzymes in patients with rheumatoid arthritis treat-ed with methotrexate. Ann Rheum Dis 2002; 61(12): 1060−4.

Cronstein BN. Low-dose methotrexate: a mainstay in the treat-ment of rheumatoid arthritis. Pharmacol Rev 2005; 57(2): 163−72.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31(3): 315−24.

Fransen J, Stucki G, Van Riel PL. Rheumatoid arthritis measures. Arthritis Rheum 2003; 49(5 Suppl): S214−24.

Wood RJ, Wiliams DG. Colorimetric determination of serum 5'-nucleotidase without deproteinisation. Clin Chem 1981; 27(3): 464−5.

Kendall MJ, Bold AM, Farr M, Hawkins CF. 5-nucleotidase in the serum and synovial fluid of patients with rheumatoid disease. Lancet 1971; 2(7732): 1012−3.

Farr M, Kendall MJ, Shuttleworth R, Meynell MJ, Hawkins CF. Source and significance of 5-nucleotidase in synovial fluid. Ann Rheum Dis 1973; 32(4): 326−30.

Pallinti V, Ganesan N, Anbazhagan M, Rajasekhar G. Serum bio-chemical markers in rheumatoid arthritis. Indian J Biochem Biophys 2009; 46(4): 342−4.

Surekha RH, Madhavi G, Srikanth BM, Jharna P, Rao UR, Jyothy A. Serum ADA and C-reactive protein in rheumatoid arthritis. Int J Hum Genet 2006; 6(3): 195−8.

Nalesnik M, Mehanovic-Nikolic J, Jandric S. Adenosine deaminase and C-reactive protein in diagnosing and monitoring of rheu-matoid arthritis. Med Glas (Zenica) 2011; 8(1): 163−8.

Yuksel H, Akoğlu TF. Serum and synovial fluid adenosine de-aminase activity in patients with rheumatoid arthritis, osteoar-thritis, and reactive arthritis. Ann Rheum Dis 1988; 47(6): 492−5.

Hitoglou S, Hatzistilianou M, Gougoustamou D, Athanassiadou F, Kotsis A, Catriu D. Adenosine deaminase activity and its isoen-zyme pattern in patients with juvenile rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 2001; 20(6): 411−6.

Zamani B, Jamali R, Jamali A. Serum adenosine deaminase may predict disease activity in rheumatoid arthritis. Rheumatol Int 2012; 32(7): 1967−75.

Cordero OJ, Salgado FJ, Mera-Varela A, Nogueira M. Serum inter-leukin-12, interleukin-15, soluble CD26, and adenosine deami-nase in patients with rheumatoid arthritis. Rheumatol Int 2001; 21(2): 69−74.

Erer B, Yilmaz G, Yilmaz FM, Koklu S. Assessment of adeno-sine deaminase levels in rheumatoid arthritis patients receiving anti-TNF-alpha therapy. Rheumatol Int 2009; 29(6): 651−4.

Demir G, Borman P, Ayhan F, Ozquin T, Kayqisiz F, Yilmez G. Se-rum adenosine deaminase level is high but not related with disease activity parameters in patients with rheumatoid arthri-tis. Open Rheumatol 2014; 8: 24−8.

Stolk JN, Boerbooms AM, De Abreu RA, Kerstens PJ, de Koning DG, de Graaf R, et al. Purine enzyme activities in recent onset rheumatoid arthritis: are there differences between patients and healthy controls? Ann Rheum Dis 1996; 55(10): 733−8.

Mehanović Nikolić J, Laloš Miljuš J, Nalesnik M, Lakić LJ, Bobić Ž, Bogdanić J, et al. The diagnostic value of anti-cyclic citrullinated peptide antibodies, adenosine deaminase activity and other potential biomarkers for predicting and monitoring rheumatoid arthritis. JMB 2008; 27(3): 383−8.

Nakamachi Y, Koshiba M, Nakazawa T, Hatachi S, Saura R, Kuro-saka M, et al. Specific increase in enzymatic activity of adeno-sine deaminase 1 in rheumatoid synovial fibroblasts. Arthritis Rheum 2003; 48(3): 668−74.

Riksen NP, Barrera P, van den Broek PH, van Riel PL, Smits P, Rongen GA. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis 2006; 65(4): 465−70.

Zivkovic N, Djindjic B, Dimic A, Aleksandric J, Milovanovic S. Im-portance of adenosine deaminase in rheumatoid arthritis diag-nosis and therapeutic effects of applied methotrexate. Health MED 2012; 6(8): 2923−8.

Boss GR, Thompson LF, Spiegelberg HL, Pichler WJ, Seegmiller JE. Age-dependency of lymphocyte ecto-5'-nucleotidase activity. J Immunol 1980; 125(2): 679−82.